Shopping Cart 0
Cart Subtotal
USD 0

Oramed Pharmaceuticals Inc (ORMP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Oramed Pharmaceuticals Inc (Oramed) engages in the research and development of novel pharmaceutical solutions, comprising an oral insulin capsule for the treatment of individuals with diabetes, and orally ingestible capsules or pills for delivery of other polypeptides. It developed a unique proprietary platform technology, Protein Oral Delivery (POD) to transform injectable treatments into oral therapies. The technology allows for the oral delivery of drugs currently administered only by injection. The company tested its technology through various animal and human studies on its two flagship products, ORMD-0801, an orally ingestible insulin capsule; and ORMD-0901, an oral GLP-1 analog (exenatide) capsule. Oramed is headquartered in Jerusalem, Israel.

Oramed Pharmaceuticals Inc (ORMP)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11

Licensing Agreements 11

Hefei Tianhui Incubator of Technologies Amends Its Licensing Agreement with Oramed Pharma 11

Oramed to Enter into Licensing Agreement with Sinopharm and Hefei Life Science 12

Guangxi Wuzhou Pharma Enters into Licensing Agreement with Oramed Pharma 13

Equity Offering 14

Oramed Pharma Raises USD18.1 Million in Private Placement of Shares 14

Oramed Pharma to Raise up to USD25 Million in Public Offering of Shares 16

Oramed Pharma Raises USD12 Million in Private Placement of Shares 17

Oramed Pharma Raises USD5.4 Million in Private Placement of Shares 18

Oramed Pharma to Raise USD5.4 Million in Private Placement of Shares 20

Oramed Pharma Completes Private Placement Of Shares For USD 15.8 Million 21

Oramed Pharma Completes Private Placement Of Shares For USD 4.6 Million 23

Oramed Pharma Withdraws Public Offering Of Common Stock For USD 13 Million 24

Oramed Pharma Completes Private Placement Of Units USD 5 Million 25

Oramed Pharma Completes Private Placement Of Units For USD 3.6 Million 26

Acquisition 27

Sinopharm and Hefei Life Science to Acquire 10% Stake In Oramed Pharma 27

Guangxi Wuzhou Pharma Acquires Stake in Oramed Pharma for USD5 Million 28

Oramed Pharmaceuticals Inc-Key Competitors 29

Oramed Pharmaceuticals Inc-Key Employees 30

Oramed Pharmaceuticals Inc-Locations And Subsidiaries 31

Head Office 31

Other Locations & Subsidiaries 31

Joint Venture 31

Recent Developments 32

Corporate Communications 32

Feb 28, 2018: Oramed Appoints Robert Henry and Jane Reusch to its Scientific Advisory Board 32

Mar 21, 2017: Oramed Appoints Dr. Ronald Law as Chief Strategy Officer 33

Product News 34

05/02/2017: Oramed Receives Israel Regulatory Approval to Conduct Human Study for New Oral Leptin Capsule 34

Appendix 35

Methodology 35

About GlobalData 35

Contact Us 35

Disclaimer 35


List Of Figure

List of Figures

Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Oramed Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 8

Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Hefei Tianhui Incubator of Technologies Amends Its Licensing Agreement with Oramed Pharma 11

Oramed to Enter into Licensing Agreement with Sinopharm and Hefei Life Science 12

Guangxi Wuzhou Pharma Enters into Licensing Agreement with Oramed Pharma 13

Oramed Pharma Raises USD18.1 Million in Private Placement of Shares 14

Oramed Pharma to Raise up to USD25 Million in Public Offering of Shares 16

Oramed Pharma Raises USD12 Million in Private Placement of Shares 17

Oramed Pharma Raises USD5.4 Million in Private Placement of Shares 18

Oramed Pharma to Raise USD5.4 Million in Private Placement of Shares 20

Oramed Pharma Completes Private Placement Of Shares For USD 15.8 Million 21

Oramed Pharma Completes Private Placement Of Shares For USD 4.6 Million 23

Oramed Pharma Withdraws Public Offering Of Common Stock For USD 13 Million 24

Oramed Pharma Completes Private Placement Of Units USD 5 Million 25

Oramed Pharma Completes Private Placement Of Units For USD 3.6 Million 26

Sinopharm and Hefei Life Science to Acquire 10% Stake In Oramed Pharma 27

Guangxi Wuzhou Pharma Acquires Stake in Oramed Pharma for USD5 Million 28

Oramed Pharmaceuticals Inc, Key Competitors 29

Oramed Pharmaceuticals Inc, Key Employees 30

Oramed Pharmaceuticals Inc, Subsidiaries 31

Oramed Pharmaceuticals Inc, Joint Venture 31

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Oramed Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Oramed Pharmaceuticals Inc (Oramed) engages in the research and development of novel pharmaceutical solutions, comprising an oral insulin capsule for the treatment of individuals with diabetes, and orally ingestible capsules or pills for delivery of other polypeptides. It developed a unique proprietary platform technology, Protein Oral Delivery (POD) to transform injectable treatments into oral therapies. The technology allows for the oral delivery of drugs currently administered only by injection. The company tested its technology through various animal and human studies on its two flagship products, ORMD-0801, an orally ingestible insulin capsule; and ORMD-0901, an oral GLP-1 analog (exenatide) capsule. Oramed is headquartered in Jerusalem, Israel.

Oramed Pharmaceuticals Inc (ORMP)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11

Licensing Agreements 11

Hefei Tianhui Incubator of Technologies Amends Its Licensing Agreement with Oramed Pharma 11

Oramed to Enter into Licensing Agreement with Sinopharm and Hefei Life Science 12

Guangxi Wuzhou Pharma Enters into Licensing Agreement with Oramed Pharma 13

Equity Offering 14

Oramed Pharma Raises USD18.1 Million in Private Placement of Shares 14

Oramed Pharma to Raise up to USD25 Million in Public Offering of Shares 16

Oramed Pharma Raises USD12 Million in Private Placement of Shares 17

Oramed Pharma Raises USD5.4 Million in Private Placement of Shares 18

Oramed Pharma to Raise USD5.4 Million in Private Placement of Shares 20

Oramed Pharma Completes Private Placement Of Shares For USD 15.8 Million 21

Oramed Pharma Completes Private Placement Of Shares For USD 4.6 Million 23

Oramed Pharma Withdraws Public Offering Of Common Stock For USD 13 Million 24

Oramed Pharma Completes Private Placement Of Units USD 5 Million 25

Oramed Pharma Completes Private Placement Of Units For USD 3.6 Million 26

Acquisition 27

Sinopharm and Hefei Life Science to Acquire 10% Stake In Oramed Pharma 27

Guangxi Wuzhou Pharma Acquires Stake in Oramed Pharma for USD5 Million 28

Oramed Pharmaceuticals Inc-Key Competitors 29

Oramed Pharmaceuticals Inc-Key Employees 30

Oramed Pharmaceuticals Inc-Locations And Subsidiaries 31

Head Office 31

Other Locations & Subsidiaries 31

Joint Venture 31

Recent Developments 32

Corporate Communications 32

Feb 28, 2018: Oramed Appoints Robert Henry and Jane Reusch to its Scientific Advisory Board 32

Mar 21, 2017: Oramed Appoints Dr. Ronald Law as Chief Strategy Officer 33

Product News 34

05/02/2017: Oramed Receives Israel Regulatory Approval to Conduct Human Study for New Oral Leptin Capsule 34

Appendix 35

Methodology 35

About GlobalData 35

Contact Us 35

Disclaimer 35


List Of Figure

List of Figures

Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Oramed Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 8

Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Hefei Tianhui Incubator of Technologies Amends Its Licensing Agreement with Oramed Pharma 11

Oramed to Enter into Licensing Agreement with Sinopharm and Hefei Life Science 12

Guangxi Wuzhou Pharma Enters into Licensing Agreement with Oramed Pharma 13

Oramed Pharma Raises USD18.1 Million in Private Placement of Shares 14

Oramed Pharma to Raise up to USD25 Million in Public Offering of Shares 16

Oramed Pharma Raises USD12 Million in Private Placement of Shares 17

Oramed Pharma Raises USD5.4 Million in Private Placement of Shares 18

Oramed Pharma to Raise USD5.4 Million in Private Placement of Shares 20

Oramed Pharma Completes Private Placement Of Shares For USD 15.8 Million 21

Oramed Pharma Completes Private Placement Of Shares For USD 4.6 Million 23

Oramed Pharma Withdraws Public Offering Of Common Stock For USD 13 Million 24

Oramed Pharma Completes Private Placement Of Units USD 5 Million 25

Oramed Pharma Completes Private Placement Of Units For USD 3.6 Million 26

Sinopharm and Hefei Life Science to Acquire 10% Stake In Oramed Pharma 27

Guangxi Wuzhou Pharma Acquires Stake in Oramed Pharma for USD5 Million 28

Oramed Pharmaceuticals Inc, Key Competitors 29

Oramed Pharmaceuticals Inc, Key Employees 30

Oramed Pharmaceuticals Inc, Subsidiaries 31

Oramed Pharmaceuticals Inc, Joint Venture 31

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Oramed Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.